Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ZURA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- 31% Opposition to Equity Plan Amendment (new) — Elevated opposition suggests shareholder concerns about dilution or compensation practices that warrant board attention.
- Two Directors Received ~29% Opposition Votes (new) — Jarrett and Munshi faced materially higher opposition than other directors, signaling potential shareholder concerns about their board service.
Zura Bio shareholders approve amended equity plan despite 31% opposition
Filed June 18, 2026 · Period ending June 17, 2026 · ~1 min read
Key Changes
-
medium
Shareholders approved the amended 2023 Equity Incentive Plan with 69.0% support (38.9M for vs 17.4M against), reflecting elevated 31% opposition that suggests meaningful shareholder concern about dilution or compensation practices.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
medium
Directors Jennifer Jarrett and Amit Munshi were re-elected but received only 70.7% and 71.5% support respectively, with over 16 million votes against each, indicating notable shareholder opposition compared to the six other directors who received over 99% support.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Shareholders ratified WithumSmith+Brown, PC as independent auditor for fiscal 2026 with 99.7% support (74.3M for vs 30,527 against), a routine approval level.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
Summary
Zura Bio's June 17, 2026 annual meeting revealed meaningful shareholder pushback on two governance matters. The amended 2023 Equity Incentive Plan passed with 69% support, but the 31% opposition (17.4 million votes against) is elevated for an equity plan proposal and suggests shareholder concerns about potential dilution or compensation practices.
Directors Jennifer Jarrett and Amit Munshi were re-elected but faced notable opposition, with each receiving only 70-71% support compared to over 99% for the six other directors. The 16+ million votes against each director signal potential shareholder concerns about their board service that the company may need to address.
For retail holders, the elevated opposition levels on both the equity plan and two directors indicate governance friction worth monitoring. While the proposals passed and the directors were re-elected, the vote patterns suggest a meaningful segment of the shareholder base has concerns about compensation practices and board composition. The company's response to this feedback in future proxy disclosures and governance decisions will be worth watching.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 17, 2026, Zura Bio Limited (the “Company”) held its Annual General Meeting of Shareholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the shareholders of the Company approved an amendment and restatement of the Company’s 2023 Equity Incentive Plan (the “Amended 2023 Plan”). The Company’s board of directors previously approved the Amended 2023 Plan on April 23, 2026, subject to approval of the shareholders at the Annual Meeting. The Amended 2023 Plan became effective immediately upon shareholder approval at the Annual Meeting.
Shareholders approved an amendment and restatement of the 2023 Equity Incentive Plan at the annual meeting. The board had previously approved the plan on April 23, 2026, contingent on shareholder approval. The amended plan became effective immediately upon approval. The material terms are described in the company's proxy statement filed April 30, 2026.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Zura Bio held its 2026 annual meeting, electing 8 directors, ratifying WithumSmith+Brown as auditor, and approving an amended equity plan.
Added in current filing · verify on EDGAR → · paraphrased
Nominee | For | Against | Abstain | Broker Non-Votes Daniel Becker | 55,968,512 | 291,173 | 20,958 | 18,267,509 Mark Eisner | 56,209,068 | 49,466 | 22,109 | 18,267,509 Jennifer Jarrett | 39,788,639 | 16,471,044 | 20,958 | 18,267,511 Amit Munshi | 40,229,829 | 16,027,697 | 23,115 | 18,267,511 Sandeep Kulkarni | 56,250,391 | 8,292 | 21,960 | 18,267,509 Ajay Nirula | 56,249,212 | 8,319 | 23,113 | 18,267,508 Steven Schoch | 56,197,526 | 61,025 | 22,093 | 18,267,508 Parvinder Thiara | 55,766,669 | 490,857 | 23,115 | 18,267,511
All eight director nominees were elected. Six directors received over 99% support from votes cast. However, Jennifer Jarrett received 70.7% support (39,788,639 for vs 16,471,044 against) and Amit Munshi received 71.5% support (40,229,829 for vs 16,027,697 against), indicating notable shareholder opposition to these two directors compared to the others.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify